Show simple item record

dc.contributor.authorDaugla, D M
dc.contributor.authorGami, J P
dc.contributor.authorGamougam, K
dc.contributor.authorNaibei, N
dc.contributor.authorMbainadji, L
dc.contributor.authorNarbé, M
dc.contributor.authorToralta, J
dc.contributor.authorKodbesse, B
dc.contributor.authorNgadoua, C
dc.contributor.authorColdiron, M E
dc.contributor.authorFermon, F
dc.contributor.authorPage, A-L
dc.contributor.authorDjingarey, M H
dc.contributor.authorHugonnet, S
dc.contributor.authorHarrison, O B
dc.contributor.authorRebbetts, L S
dc.contributor.authorTekletsion, Y
dc.contributor.authorWatkins, E R
dc.contributor.authorHill, D
dc.contributor.authorCaugant, D A
dc.contributor.authorChandramohan, D
dc.contributor.authorHassan-King, M
dc.contributor.authorManigart, O
dc.contributor.authorNascimento, M
dc.contributor.authorWoukeu, A
dc.contributor.authorTrotter, C
dc.contributor.authorStuart, J M
dc.contributor.authorMaiden, M C J
dc.contributor.authorGreenwood, B M
dc.date.accessioned2013-09-24T20:47:45Z
dc.date.available2013-09-24T20:47:45Z
dc.date.issued2013-09-11
dc.identifier.citationEffect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial. 2013: Lanceten_GB
dc.identifier.issn1474-547X
dc.identifier.pmid24035220
dc.identifier.doi10.1016/S0140-6736(13)61612-8
dc.identifier.urihttp://hdl.handle.net/10144/302225
dc.description.abstractA serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) was licensed in India in 2009, and pre-qualified by WHO in 2010, on the basis of its safety and immunogenicity. This vaccine is now being deployed across the African meningitis belt. We studied the effect of PsA-TT on meningococcal meningitis and carriage in Chad during a serogroup A meningococcal meningitis epidemic.
dc.languageENG
dc.language.isoenen
dc.publisherElsevieren_GB
dc.rightsReproduced on this site with permission of Elsevier Ltd. Please see [url]http://www.thelancet.com/[/url] for further relevant comment.en_GB
dc.subjectMeningitisen_GB
dc.subjectVaccinationen_GB
dc.titleEffect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trialen
dc.contributor.departmentCentre de Support en Santé International (CSSI), N'Djamena, Chad.en_GB
dc.identifier.journalLanceten_GB
refterms.dateFOA2019-03-04T10:46:30Z
html.description.abstractA serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) was licensed in India in 2009, and pre-qualified by WHO in 2010, on the basis of its safety and immunogenicity. This vaccine is now being deployed across the African meningitis belt. We studied the effect of PsA-TT on meningococcal meningitis and carriage in Chad during a serogroup A meningococcal meningitis epidemic.


Files in this item

Thumbnail
Name:
Daugla et al. - 2013 - Effect ...
Size:
732.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record